Khokhar Arif A, Ponticelli Francesco, Zlahoda-Huzior Adriana, Chandra Kailash, Ruggiero Rossella, Toselli Marco, Gallo Francesco, Cereda Alberto, Sticchi Alessandro, Laricchia Alessandra, Regazzoli Damiano, Mangieri Antonio, Reimers Bernhard, Biscaglia Simone, Tumscitz Carlo, Campo Gianluca, Mikhail Ghada W, Kim Won-Keun, Colombo Antonio, Dudek Dariusz, Giannini Francesco
Department of Cardiology, Imperial College Healthcare National Health Service (NHS) Trust, London, United Kingdom.
Digital Innovations and Robotics Hub, Kraków, Poland.
Front Cardiovasc Med. 2022 Sep 14;9:902564. doi: 10.3389/fcvm.2022.902564. eCollection 2022.
Coronary access after transcatheter aortic valve implantation (TAVI) with supra-annular self-expandable valves may be challenging or un-feasible. There is little data concerning coronary access following transcatheter aortic valve-in-valve implantation (ViV-TAVI) for degenerated surgical bioprosthesis.
To evaluate the feasibility and challenge of coronary access after ViV-TAVI with the supra-annular self-expandable ACURATE neo valve.
Sixteen patients underwent ViV-TAVI with the ACURATE neo valve. Post-procedural computed tomography (CT) was used to create 3D-printed life-sized patient-specific models for bench-testing of coronary cannulation. Primary endpoint was feasibility of diagnostic angiography and PCI. Secondary endpoints included incidence of challenging cannulation for both diagnostic catheters (DC) and guiding catheters (GC). The association between challenging cannulations with aortic and transcatheter/surgical valve geometry was evaluated using pre and post-procedural CT scans.
Diagnostic angiography and PCI were feasible for 97 and 95% of models respectively. All non-feasible procedures occurred in ostia that underwent prophylactic "chimney" stenting. DC cannulation was challenging in 17% of models and was associated with a narrower SoV width (30 vs. 35 mm, < 0.01), STJ width (28 vs. 32 mm, < 0.05) and shorter STJ height (15 vs. 17 mm, < 0.05). GC cannulation was challenging in 23% of models and was associated with narrower STJ width (28 vs. 32 mm, < 0.05), smaller transcatheter-to-coronary distance (5 vs. 9.2 mm, < 0.05) and a worse coronary-commissural overlap angle (14.3° vs. 25.6 , < 0.01). Advanced techniques to achieve GC cannulation were required in 22/64 (34%) of cases.
In this exploratory bench analysis, diagnostic angiography and PCI was feasible in almost all cases following ViV-TAVI with the ACURATE neo valve. Prophylactic coronary stenting, higher implantation, narrower aortic sinus dimensions and commissural misalignment were associated with an increased challenge of coronary cannulation.
使用瓣环上自膨胀瓣膜进行经导管主动脉瓣植入术(TAVI)后进行冠状动脉通路建立可能具有挑战性或不可行。关于经导管主动脉瓣瓣中瓣植入术(ViV-TAVI)治疗退化的外科生物假体后冠状动脉通路的数据很少。
评估使用瓣环上自膨胀ACURATE neo瓣膜进行ViV-TAVI后冠状动脉通路建立的可行性和挑战性。
16例患者接受了ACURATE neo瓣膜的ViV-TAVI。术后计算机断层扫描(CT)用于创建3D打印的真人大小的患者特异性模型,用于冠状动脉插管的体外测试。主要终点是诊断性血管造影和经皮冠状动脉介入治疗(PCI)的可行性。次要终点包括诊断导管(DC)和引导导管(GC)插管困难的发生率。使用术前和术后CT扫描评估插管困难与主动脉及经导管/外科瓣膜几何形状之间的关联。
诊断性血管造影和PCI在分别97%和95%的模型中可行。所有不可行的操作均发生在接受预防性“烟囱”支架置入术的开口处。17%的模型中DC插管具有挑战性,且与较窄的瓣叶间宽度(30对35mm,<0.01)、窦管交界宽度(28对32mm,<0.05)和较短的窦管交界高度(15对17mm,<0.05)相关。23%的模型中GC插管具有挑战性,且与较窄的窦管交界宽度(28对32mm,<0.05)、较小的经导管至冠状动脉距离(5对9.2mm,<0.05)和较差的冠状动脉-瓣叶交界重叠角(14.3°对25.6°,<0.01)相关。22/64(34%)的病例需要采用先进技术来实现GC插管。
在这项探索性的体外分析中,使用ACURATE neo瓣膜进行ViV-TAVI后,几乎所有病例的诊断性血管造影和PCI都是可行的。预防性冠状动脉支架置入术、较高的植入位置、较窄的主动脉窦尺寸和瓣叶交界错位与冠状动脉插管难度增加相关。